ICON Public FY2024 EPS Estimate Lifted by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Leerink Partnrs upped their FY2024 earnings per share estimates for shares of ICON Public in a research report issued to clients and investors on Tuesday, January 14th. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings per share of $13.40 for the year, up from their previous estimate of $13.25. The consensus estimate for ICON Public’s current full-year earnings is $13.41 per share.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same quarter in the previous year, the company posted $3.10 EPS. The company’s quarterly revenue was down 1.2% on a year-over-year basis.

ICLR has been the topic of a number of other research reports. JPMorgan Chase & Co. dropped their price target on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. StockNews.com downgraded shares of ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Tuesday. Barclays dropped their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Finally, Evercore ISI lowered their price target on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $287.00.

ICON Public Stock Up 1.5 %

ICLR opened at $202.47 on Thursday. The business’s 50-day simple moving average is $210.30 and its 200-day simple moving average is $269.51. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. ICON Public has a one year low of $183.38 and a one year high of $347.72. The stock has a market capitalization of $16.70 billion, a P/E ratio of 22.57, a price-to-earnings-growth ratio of 1.59 and a beta of 1.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Foyston Gordon & Payne Inc acquired a new stake in shares of ICON Public in the third quarter valued at about $11,672,000. Icon Wealth Advisors LLC increased its holdings in ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after buying an additional 11,840 shares in the last quarter. Sara Bay Financial acquired a new stake in shares of ICON Public during the 3rd quarter valued at approximately $1,143,000. Whittier Trust Co. boosted its stake in shares of ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after acquiring an additional 441 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after acquiring an additional 169 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.